4-chloro-3-piperidin-1-yl-benzoic acid | 886501-28-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-chloro-3-piperidin-1-yl-benzoic acid
• 英文别名: 4-chloro-3-piperidin-1-ylbenzoic acid
• CAS: 886501-28-6
• 化学式: C₁₂H₁₄ClNO₂
• mdl: MFCD06740052
• 分子量: 239.702
• InChiKey: AWYXXFCRDASAPP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-chloro-3-piperidin-1-yl-benzoic acid 、 3-{[(furan-2-ylmethyl)-amino]-methyl}-6-methyl-1H-quinolin-2-one 在 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 8.5h， 以48%的产率得到4-chloro-N-furan-2-ylmethyl-N-(6-methyl-2-oxo-1,2-dihydro-quinolin-3-ylmethyl)-3-piperidin-1-yl-benzamide
  参考文献：
  名称：

  Virtual screening based identification of novel small-molecule inhibitors targeted to the HIV-1 capsid

  摘要：

  The hydrophobic cavity of the C-terminal domain (CTD) of HIV-1 capsid has been recently validated as potential target for antiviral drugs by peptide-based inhibitors; however, there is no report yet of any small molecule compounds that target this hydrophobic cavity. In order to fill this gap and discover new classes of ant-HIV-1 inhibitors, we undertook a docking-based virtual screening and subsequent analog search, and medicinal chemistry approaches to identify small molecule inhibitors against this target. This article reports for the first time, to the best of our knowledge, identification of diverse classes of inhibitors that efficiently inhibited the formation of mature-like viral particles verified under electron microscope (EM) and showed potential as anti-HIV-1 agents in a viral infectivity assay against a wide range of laboratory-adapted as well as primary isolates in MT-2 cells and PBMC. In addition, the virions produced after the HIV-1 infected cells were treated with two of the most active compounds showed drastically reduced infectivity confirming the potential of these compounds as anti-HIV-1 agents. We have derived a comprehensive SAR from the antiviral data. The SAR analyses will be useful in further optimizing the leads to potential anti-HIV-1 agents. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.11.045

文献信息

• Substituted phenylimidazopyrazoles and their use
  申请人：BAYER INTELLECTUAL PROPERTY GmbH

  公开号：US20130190290A1

  公开（公告）日：2013-07-25

  The present application relates to novel 1-phenyl-1H-imidazo[1,2-b]pyrazole derivatives, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular angiogenic disorders and hyperproliferative disorders, where neovascularization plays a role, such as, for example, neoplastic disorders and tumour disorders. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.

  本申请涉及新颖的1-苯基-1H-咪唑[1,2-b]吡唑衍生物，其制备方法，其用于治疗和/或预防疾病以及用于制备用于治疗和/或预防疾病的药物，特别是血管生成障碍和过度增殖障碍，其中血管新生起到作用，例如肿瘤性疾病和肿瘤性疾病。这种治疗可以作为单独治疗，也可以与其他药物或其他治疗措施结合使用。
• SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF
  申请人：Bayer Intellectual Property GmbH

  公开号：US20150005288A1

  公开（公告）日：2015-01-01

  The present application relates to novel 1-phenyl-1H-imidazo[1,2-b]pyrazole derivatives, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular angiogenic disorders and hyperproliferative disorders, where neovascularization plays a role, such as, for example, neoplastic disorders and tumour disorders. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.

  本申请涉及新型1-苯基-1H-咪唑[1,2-b]吡唑衍生物，其制备过程，其用于治疗和/或预防疾病以及其用于制备治疗和/或预防疾病的药物，特别是血管生成障碍和增生性疾病，其中新生血管化起到作用，例如肿瘤性疾病和肿瘤性疾病。这种治疗可以作为单一疗法进行，也可以与其他药物或进一步治疗措施结合使用。
• SUBSTITUIERTE PHENYLIMIDAZOPYRAZOLE UND IHRE VERWENDUNG
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：EP2807162B1

  公开（公告）日：2017-06-07
• US9394309B2
  申请人：——

  公开号：US9394309B2

  公开（公告）日：2016-07-19
• [DE] SUBSTITUIERTE PHENYLIMIDAZOPYRAZOLE UND IHRE VERWENDUNG<br/>[EN] SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF<br/>[FR] PHÉNYLIMIDAZOPYRAZOLES SUBSTITUÉS ET LEUR UTILISATION
  申请人：BAYER PHARMA AG

  公开号：WO2013110590A1

  公开（公告）日：2013-08-01

  Die vorliegende Anmeldung betrifft neue 1-Phenyl-1H-imidazo[1,2-b]pyrazol-Derivate der Formel (I), Verfahren zu ihrer Herstellung, ihre Verwendung zur Behandlung und/oder Prävention von Krankheiten sowie ihre Verwendung zur Herstellung von Arzneimitteln zur Behandlung und/oder Prävention von Krankheiten, insbesondere von angiogenen Erkrankungen und hyperproliferativen Erkrankungen, bei denen Neovaskularisierung eine Rolle spielt, wie beispielsweise Krebs- und Tumorerkrankungen. Solche Behandlungen können als Monotherapie oder auch in Kombination mit anderen Arzneimitteln oder weiteren therapeutischen Maßnahmen erfolgen.